Pulmonary Arterial Hypertension Market Size

Pulmonary Arterial Hypertension (PAH) Market size exceeded USD 6.6 billion in 2020 and is anticipated to grow at a CAGR of 6% between 2021 and 2027. The strong product pipeline and novel drug combination awaiting approval are expected to boost the market growth. Furthermore, pulmonary arterial hypertension is a rare lung disorder that is commonly reported in children. The high proportion of children suffering from untreated PAH offers immense market expansion opportunities and is poised to promote the use of pulmonary arterial hypertension drugs.

However, side effects associated with the drugs may negatively influence the market progression. Vasodilators are widely prescribed for the treatment of patients with PAH to open blocked and narrowed blood vessels. Studies report that vasodilators have a number of side effects such as tachycardia, edema, heart palpitations, chest pain, etc. Owing to the substantial side effects associated with the use of vasodilators in chronically ill patients, the U.S. FDA regulates the use of this drug. Further, the PAH drugs that treat high blood pressure and dilate blood vessels require to submit reasonable assurance regarding the safety and effectiveness of the drugs. These drugs require the U.S. FDA approval before commercializing in the market. The FDA drug approval represents a complicated process that demonstrates the safety and efficacy of the drug. Hence, a time-consuming regulatory process and side effects related to the use of PAH drugs might hamper the industry growth during the forecast timeframe.

The pulmonary arterial hypertension market has been slightly impacted credited to the COVID-19 and the slender effects of the coronavirus pandemic may remain in the coming years. The impact of coronavirus outbreak on the industry peaked during early 2020 wherein, pulmonary arterial hypertension patients were at a higher risk of suffering from coronavirus. Other challenges including hindrance in diagnostic testing, changed guidelines pertaining to the hospital & emergency care, and interrupted drug supply chain among others had impeded the industry expansion. The pandemic has exhibited the importance of PAH drugs as a response to the increasing number of hospitalized PAH-COVID-19 patients.